ZOTA2025-04-012025-06-30ZOTA2025-06-30ZOTA2025-04-012025-06-30in-capmkt:OtherExpenses1MemberZOTA2025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1ZOTA2025-06-30Statement1ZOTA2025-04-012025-06-30Statement1ZOTA2025-06-30Statement2ZOTA2025-04-012025-06-30Statement2ZOTA2025-06-30Statement3ZOTA2025-04-012025-06-30Statement3ZOTA2025-06-30StatementDynamic1I1Statement1ZOTA2025-06-30StatementDynamic1I2Statement1ZOTA2025-06-30StatementDynamic1I3Statement1ZOTA2025-06-30StatementDynamic2I1Statement2ZOTA2025-06-30StatementDynamic2I2Statement2ZOTA2025-06-30StatementDynamic2I3Statement2ZOTA2025-06-30StatementDynamic2I4Statement2ZOTA2025-06-30StatementDynamic3I1Statement3ZOTA2025-06-30StatementDynamic3I2Statement3ZOTA2025-06-30StatementDynamic3I3Statement3ZOTA2025-06-30StatementDynamic3I4Statement3iso4217:INRxbrli:pureiso4217:INRxbrli:shares000000ZOTANOTLISTEDINE358U01012ZOTA HEALTH CARE LIMITEDMain BoardEquity2025-04-012026-03-312025-08-082025-08-01INRLakhsQuarterlyFirst quarterSingle segmentManufacturing and marketing of pharmaceutical prdoucts2025-08-0814:00:002025-08-0817:00:00Not applicabletrue3falseDuring the quarter, the Company has not made any default on repayment of Loan. Further, the Company has not issued any Debt Securities till date.2025-04-012025-06-30UnauditedStandalone7800700002233900080240900049052000344221000536900009975800036800079680001618960007169530008545600008545600022368000404400026412000059044000000059044000-120400057840000297666000102.031.88002.031.88As per attachmentOther Expenses161896000DEFINED BENEFIT PLAN-1609000-1609000-4050000-1204000Preferential Issues2024-08-1417907280002025-06-30trueCRISIL RATINGS LIMITEDfalseThe Committee has noted that there is no deviation or variation.No commentsAshvin VariyaCompany Secretary and Compliance OfficerSurat2025-08-08Preferential Issues2025-02-2012341000002025-06-30trueCRISIL RATINGS LIMITEDfalseThe Committee has noted that there is no deviation or variation.No commentsPreferential Issues2025-04-177155000002025-06-30falsefalseThe Committee noted that during the quarter, no funds have been utilized against the stated objectesNo commentsExpansion of DAVAINDIA ProjectNot Applicable143258300008230390000Out of the issue proceeds of Rs 17907.28 lakhs, the Company has received issue proceeds of Rs 10908.37 lakhs till the quarter ended June 30, 2025. Further, the balance amount Rs 6998.91 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. February 13, 2026, as per the Notice to Shareholders dated July 13, 2024.Working capital requirementNot Applicable26860900001918870000Out of the issue proceeds of Rs 17907.28 lakhs, the Company has received issue proceeds of Rs 10908.37 lakhs till the quarter ended June 30, 2025. Further, the balance amount Rs 6998.91 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. February 13, 2026, as per the Notice to Shareholders dated July 13, 2024.General Corporate PurposeNot Applicable895360000349110000Out of the issue proceeds of Rs 17907.28 lakhs, the Company has received issue proceeds of Rs 10908.37 lakhs till the quarter ended June 30, 2025. Further, the balance amount Rs 6998.91 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. February 13, 2026, as per the Notice to Shareholders dated July 13, 2024.Expansion of DAVAINDIA Project FOFONot Applicable1604330000928070000Out of the issue proceeds of Rs 12341.00 lakhs, the Company has received issue proceeds of Rs 7713.13 lakhs till the quarter ended June 30, 2025.The balance amount Rs 4627.88 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. August 20, 2027, as per the Notice to Shareholders dated February 05, 2025.Expansion of DAVAINDIA Project COCONot Applicable76514200002893540000Out of the issue proceeds of Rs 12341.00 lakhs, the Company has received issue proceeds of Rs 7713.13 lakhs till the quarter ended June 30, 2025.The balance amount Rs 4627.88 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. August 20, 2027, as per the Notice to Shareholders dated February 05, 2025.Working capital requirementNot Applicable1234100000862170000Out of the issue proceeds of Rs 12341.00 lakhs, the Company has received issue proceeds of Rs 7713.13 lakhs till the quarter ended June 30, 2025.The balance amount Rs 4627.88 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. August 20, 2027, as per the Notice to Shareholders dated February 05, 2025.General Corporate PurposeNot Applicable18511500001694340000Out of the issue proceeds of Rs 12341.00 lakhs, the Company has received issue proceeds of Rs 7713.13 lakhs till the quarter ended June 30, 2025.The balance amount Rs 4627.88 lakhs is expected to be received by the warrant holders at the time of exercising the conversion rights, on or before the expiry of 18 months from the date of allotment of the Warrants i.e. August 20, 2027, as per the Notice to Shareholders dated February 05, 2025.Expansion of DAVAINDIA Project FOFONot Applicable93015000000Expansion of DAVAINDIA Project COCONot Applicable479385000000Working capital requirementNot Applicable71550000000General Corporate PurposeNot Applicable71550000000